JP2023510205A - 磁気共鳴イメージングにおけるデオキシヘモグロビン - Google Patents
磁気共鳴イメージングにおけるデオキシヘモグロビン Download PDFInfo
- Publication number
- JP2023510205A JP2023510205A JP2022540763A JP2022540763A JP2023510205A JP 2023510205 A JP2023510205 A JP 2023510205A JP 2022540763 A JP2022540763 A JP 2022540763A JP 2022540763 A JP2022540763 A JP 2022540763A JP 2023510205 A JP2023510205 A JP 2023510205A
- Authority
- JP
- Japan
- Prior art keywords
- subject
- deoxyhemoglobin
- magnetic resonance
- resonance imaging
- gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 title claims abstract description 77
- 108010002255 deoxyhemoglobin Proteins 0.000 title claims abstract description 77
- 238000002595 magnetic resonance imaging Methods 0.000 title claims abstract description 69
- 239000002872 contrast media Substances 0.000 claims abstract description 36
- 230000017531 blood circulation Effects 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims description 98
- 239000007789 gas Substances 0.000 claims description 69
- 210000004369 blood Anatomy 0.000 claims description 42
- 239000008280 blood Substances 0.000 claims description 42
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 34
- 230000008859 change Effects 0.000 claims description 34
- 239000001301 oxygen Substances 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 230000003727 cerebral blood flow Effects 0.000 claims description 20
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 19
- 230000002685 pulmonary effect Effects 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 16
- 239000001569 carbon dioxide Substances 0.000 claims description 15
- 238000003384 imaging method Methods 0.000 claims description 14
- 230000036961 partial effect Effects 0.000 claims description 11
- 230000000747 cardiac effect Effects 0.000 claims description 10
- 238000012905 input function Methods 0.000 claims description 10
- 230000010412 perfusion Effects 0.000 claims description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 9
- 210000000709 aorta Anatomy 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 230000002861 ventricular Effects 0.000 claims description 7
- 210000005166 vasculature Anatomy 0.000 claims description 3
- 206010006322 Breath holding Diseases 0.000 claims description 2
- 206010021133 Hypoventilation Diseases 0.000 claims description 2
- 229940100563 gas for inhalation Drugs 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 230000000287 tissue oxygenation Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000036391 respiratory frequency Effects 0.000 claims 2
- 230000003068 static effect Effects 0.000 claims 2
- 238000012800 visualization Methods 0.000 claims 2
- 206010003226 Arteriovenous fistula Diseases 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- 238000002592 echocardiography Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000005245 right atrium Anatomy 0.000 claims 1
- 238000006213 oxygenation reaction Methods 0.000 abstract description 6
- 230000001419 dependent effect Effects 0.000 abstract description 5
- 230000005291 magnetic effect Effects 0.000 abstract description 3
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 abstract description 2
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 description 21
- 210000001147 pulmonary artery Anatomy 0.000 description 21
- 108010054147 Hemoglobins Proteins 0.000 description 17
- 102000001554 Hemoglobins Human genes 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 13
- 206010021143 Hypoxia Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 10
- 229910052688 Gadolinium Inorganic materials 0.000 description 9
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 9
- 210000001367 artery Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- 239000000700 radioactive tracer Substances 0.000 description 7
- 210000005240 left ventricle Anatomy 0.000 description 6
- 210000003492 pulmonary vein Anatomy 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000013914 atrial heart septal defect Diseases 0.000 description 4
- 230000007959 normoxia Effects 0.000 description 4
- 238000011022 operating instruction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000008337 systemic blood flow Effects 0.000 description 3
- 208000035478 Interatrial communication Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010003664 atrial septal defect Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000003130 ventricular septal defect Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241001165704 Isocapnia Species 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 210000004298 cerebral vein Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000001646 magnetic resonance method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0816—Measuring devices for examining respiratory frequency
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
- A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
- A61B5/0044—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0263—Measuring blood flow using NMR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7285—Specific aspects of physiological measurement analysis for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal
- A61B5/7289—Retrospective gating, i.e. associating measured signals or images with a physiological event after the actual measurement or image acquisition, e.g. by simultaneously recording an additional physiological signal during the measurement or image acquisition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/50—NMR imaging systems based on the determination of relaxation times, e.g. T1 measurement by IR sequences; T2 measurement by multiple-echo sequences
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/58—Calibration of imaging systems, e.g. using test probes, Phantoms; Calibration objects or fiducial markers such as active or passive RF coils surrounding an MR active material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Optics & Photonics (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Cardiology (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Pulmonology (AREA)
- Mathematical Physics (AREA)
- Hematology (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本願は、2019年12月31日に出願された米国仮出願第62/955998号明細書、2020年2月26日に出願された米国仮出願第62/981949号明細書および2020年5月15日に出願された米国仮出願第63/025403号明細書の利益を主張するものであり、これらは参照によって本明細書に組み込まれる。
本発明は、米国国立衛生研究所(NIH:National Institutes of Health)から授与された、助成(または契約)U01HL117718号および助成(または契約)RO1HL136484号の下で政府支援により行われたものである。政府は、本発明に一定の権利を有する。
Claims (35)
- 被検体においてデオキシヘモグロビンの変化を生成するステップと、
前記被検体に磁気共鳴イメージングを行うステップと、
前記磁気共鳴イメージングの強調イメージングのための造影剤として前記被検体の前記デオキシヘモグロビンを用いることと、
を有する方法。 - 前記方法は、デオキシヘモグロビンのレベルと、前記磁気共鳴イメージングのデータと、を同期させるステップをさらに有する、
請求項1記載の方法。 - 前記方法は、前記磁気共鳴イメージング中に前記被検体におけるデオキシヘモグロビンのレベルにおいて、異なる時間的かつ/または局所的応答を呈するように呼吸速度およびガス組成のうちの一方または両方を制御するステップをさらに有する、
請求項1の方法。 - 前記強調イメージングは、横緩和時間(T2)の重み付けイメージング(T2*)を有する、
請求項1記載の方法。 - 前記被検体における前記デオキシヘモグロビンの前記変化を生成するステップは、前記被検体の肺における酸素の分圧を変化させるステップを有する、
請求項1記載の方法。 - 前記方法は、前記被検体による吸入用に準備される酸素濃度の迅速かつ制御された変化に応じて、造影剤用の単一または複数のグラジエントエコーと、デオキシヘモグロビンの動的変化を示すシングルショット信号と、を使用するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、単一または複数のスピンエコー造影剤およびシングルショット信号を使用して、デオキシヘモグロビンの変化によって生じる磁気共鳴イメージング信号における強調変化を検出し、これによって血流、血液量、通過時間またはこれらの組み合わせを測定するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、造影剤用のグラジエントエコーおよびスピンエコーの組み合わせと、デオキシヘモグロビンの変化によって生じる磁気共鳴イメージング信号における混合型のT2およびT2*強調変化を示すシングルショット信号と、を使用し、これによって血流、血液量、通過時間またはこれらの組み合わせを測定するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、デオキシヘモグロビンの変化に応じて、磁気共鳴イメージング信号から、ピーク信号変化量、始まり、ピーク到達時間、半値全幅、回復半減期、曲線下面積、またはこれらの組み合わせを導出するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、ボクセルの集合を定めるために、磁気共鳴イメージング信号の特性にフーリエ解析を適用するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、動静脈瘻、側副血管、またはその両方の診断に使用することを目的として、動脈通過時間、毛細血管通過時間、静脈通過時間またはこれらの組み合わせのマップを生成するために前記フーリエ解析を適用するステップをさらに有する、
請求項10記載の方法。 - 前記方法は、血管系の静的可視化を形成するために、前記フーリエ解析の位相マップから得られる時間遅れ情報を適用するステップをさらに有する、
請求項10記載の方法。 - 前記方法は、血管系の静的可視化を形成するために、前記フーリエ解析の位相マップから得られる時間遅れ情報を適用するステップをさらに有する、
請求項10記載の方法。 - 前記方法は、造影剤が、異なる血管レベル間を連続して通過するときの動的コントラスト変化のビデオを出力するために、前記フーリエ解析の位相マップからの得られる時間遅れ情報を適用するステップをさらに有する、
請求項10記載の方法。 - 前記方法は、前記被検体における前記デオキシヘモグロビンを変化させるボーラス吸入への応答に基づいて、灌流量を計算するステップをさらに有する、
請求項1記載の方法。 - 前記灌流量は、脳血流量(CBF)、脳血液量(CBV)、平均通過時間(MTT)、動脈到達時間(ATT)、またはこれらの組み合わせを有する、
請求項15記載の方法。 - 前記方法は、動脈入力関数(AIF)を計算するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、前記磁気共鳴イメージングの信号の領域またはボクセル内の通過時間の分布を基準として、毛細血管通過時間不均一性(CTH)を特定するステップをさらに有する、
請求項1記載の方法。 - 前記方法は、前記被検体の左室のパフォーマンスステータスを計算するステップをさらに有し、前記パフォーマンスステータスは、心拍出量(Q・)、一回拍出量(SV)、または左室駆出率(LVEF)を有する、
請求項1記載の方法。 - 磁気共鳴イメージングにおける造影剤としての、被検体のデオキシヘモグロビンの使用方法。
- 被検体におけるデオキシヘモグロビンを制御する方法であって、前記方法は、
前記被検体の血液中のデオキシヘモグロビンの目標レベルを得ることを目的として、目標肺酸素分圧および目標肺二酸化炭素分圧を得るために、前記被検体が吸入するガスを供給するステップを有する、
方法。 - 前記方法は、前記被検体に前記ガスを供給するために、順次ガス供給装置を使用するステップをさらに有する、
請求項21記載の方法。 - デオキシヘモグロビンの前記目標レベルは、動脈性である、
請求項21または22記載の方法。 - デオキシヘモグロビンの前記目標レベルは、静脈性である、
請求項21または22記載の方法。 - 前記被検体が吸入するための前記ガスを供給することにより、肺酸素分圧および肺二酸化炭素分圧の迅速な変化を生じさせて、デオキシヘモグロビンを迅速に変化させる、
請求項21から24までのいずれか1項記載の方法。 - 前記方法は、前記目標肺酸素分圧および前記目標肺二酸化炭素分圧の一方または両方を得るために、動的な呼吸終期強制を使用するステップをさらに有する、
請求項21から25までのいずれか1項記載の方法。 - 前記方法は、呼吸量および呼吸頻度に依存せずに、先見的に前記目標肺酸素分圧を目標とするステップをさらに有する、
請求項21から26までのいずれか1項記載の方法。 - 前記方法は、呼吸量および呼吸頻度に依存せずに、先見的に前記目標肺二酸化炭素分圧を目標とするステップをさらに有する、
請求項21から27までのいずれか1項記載の方法。 - 前記方法は、デオキシヘモグロビンの刺激持続時間およびベースラインレベルを得るために、呼吸速度およびガス組成の一方または両方を制御するステップをさらに有する、
請求項21記載の方法。 - 前記方法は、アトラスを生成するために複数の被検体について、デオキシヘモグロビンの刺激持続時間およびベースラインレベルを得るステップをさらに有する、
請求項29記載の方法。 - 磁気共鳴イメージングにおける造影剤として使用することを目的として、被検体においてデオキシヘモグロビンを生成するための、前記被検体に換気過少および/または息こらえの使用方法。
- 磁気共鳴イメージングを較正する方法であって、前記方法は、
肺酸素分圧および肺二酸化炭素分圧を供給するガスを被検体に投与することにより、前記被検体における血中デオキシヘモグロビンを制御するステップと、
前記被検体における前記血中デオキシヘモグロビンを制御しながら、較正磁気共鳴イメージング信号を取り込むステップと、
前記血中デオキシヘモグロビンと前記較正磁気共鳴イメージング信号との関係を得るステップと、
組織酸素化情報を得るために、組織に対する後続の磁気共鳴イメージング信号に前記関係を適用するステップと、
を有する方法。 - 前記方法は、肺酸素分圧および肺二酸化炭素分圧の異なるレベルを設けるために、前記ガスを被検体に投与するステップを有する、
請求項32記載の方法。 - 前記較正磁気共鳴イメージング信号は、前記被検体の大動脈から得られる、
請求項32記載の方法。 - 前記較正磁気共鳴イメージング信号は、前記被検体の大静脈または右心房から得られる、
請求項32記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962955998P | 2019-12-31 | 2019-12-31 | |
US62/955,998 | 2019-12-31 | ||
US202062981949P | 2020-02-26 | 2020-02-26 | |
US62/981,949 | 2020-02-26 | ||
US202063025403P | 2020-05-15 | 2020-05-15 | |
US63/025,403 | 2020-05-15 | ||
PCT/IB2020/062602 WO2021137196A1 (en) | 2019-12-31 | 2020-12-31 | Deoxyhemoglobin in magnetic resonance imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023510205A true JP2023510205A (ja) | 2023-03-13 |
Family
ID=76686581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022540763A Pending JP2023510205A (ja) | 2019-12-31 | 2020-12-31 | 磁気共鳴イメージングにおけるデオキシヘモグロビン |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230056088A1 (ja) |
EP (1) | EP4084696A4 (ja) |
JP (1) | JP2023510205A (ja) |
CN (1) | CN116133598A (ja) |
CA (1) | CA3166517A1 (ja) |
WO (1) | WO2021137196A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023286040A1 (en) * | 2021-07-16 | 2023-01-19 | Joseph Arnold Fisher | Implementing a periodic deoxyhemoglobin signal |
WO2023286039A1 (en) * | 2021-07-16 | 2023-01-19 | Joseph Arnold Fisher | Inducing deoxyhemoglobin as a contrast agent in a subject for mri |
WO2023053066A1 (en) * | 2021-09-29 | 2023-04-06 | Thornhill Scientific Inc. | Identifying the vascularity of cerebral tissue in subjects using deoxyhemoglobin contrast |
CN114377155B (zh) * | 2022-01-14 | 2023-11-10 | 吴诗熳 | 一种造影剂、造影剂的制备方法及其应用 |
CN114376556A (zh) * | 2022-01-14 | 2022-04-22 | 吴诗熳 | 一种造影剂的制备方法、造影剂及其应用 |
CN114377157A (zh) * | 2022-01-14 | 2022-04-22 | 吴诗熳 | 一种造影剂制备方法、造影剂及其应用 |
US20230270348A1 (en) * | 2022-02-25 | 2023-08-31 | Thornhill Scientific Inc. | System and method for determining arterial input function based on susceptibility contrast in the choroid plexus |
WO2023161901A1 (en) * | 2022-02-25 | 2023-08-31 | Thornhill Scientific Inc. | Dynamic susceptibility contrast using a pre-determined arterial input function |
WO2024052836A1 (en) * | 2022-09-07 | 2024-03-14 | Thornhill Scientific Inc. | Providing intermittent hypoxia with sequential gas delivery |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030201773A1 (en) * | 1998-10-12 | 2003-10-30 | Stefan Posse | Measuring device, nuclear magnetic reasonance tomograph, measuring method and imaging method |
US7069068B1 (en) * | 1999-03-26 | 2006-06-27 | Oestergaard Leif | Method for determining haemodynamic indices by use of tomographic data |
US8844528B2 (en) | 2003-02-18 | 2014-09-30 | Joseph Fisher | Breathing circuits to facilitate the measurement of cardiac output during controlled and spontaneous ventilation |
US20050085705A1 (en) * | 2003-10-21 | 2005-04-21 | Rao Stephen M. | fMRI system for use in detecting neural abnormalities associated with CNS disorders and assessing the staging of such disorders |
GB0616810D0 (en) * | 2006-08-25 | 2006-10-04 | Greater Glasgow Nhs Board | Method of imaging metabolic function |
US8837800B1 (en) * | 2011-10-28 | 2014-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | Automated detection of arterial input function and/or venous output function voxels in medical imaging |
EP2592431A1 (en) * | 2011-11-11 | 2013-05-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method and apparatus for visualization of tissue perfusion by means of assessing BOLD signal fluctuations |
EP2788063B1 (en) | 2011-12-05 | 2023-05-03 | Thornhill Scientific Inc. | An apparatus to attain and maintain target end tidal partial pressure of a gas |
GB201221305D0 (en) | 2012-11-27 | 2013-01-09 | Greater Glasgow Health Board | Improved methods of assessing metabolic function |
WO2013138910A1 (en) | 2012-03-19 | 2013-09-26 | Michael Klein | Virtual respiratory gas delivery systems and circuits |
-
2020
- 2020-12-31 WO PCT/IB2020/062602 patent/WO2021137196A1/en unknown
- 2020-12-31 CN CN202080097810.7A patent/CN116133598A/zh active Pending
- 2020-12-31 JP JP2022540763A patent/JP2023510205A/ja active Pending
- 2020-12-31 CA CA3166517A patent/CA3166517A1/en active Pending
- 2020-12-31 US US17/789,732 patent/US20230056088A1/en active Pending
- 2020-12-31 EP EP20910462.9A patent/EP4084696A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116133598A (zh) | 2023-05-16 |
US20230056088A1 (en) | 2023-02-23 |
EP4084696A4 (en) | 2024-01-10 |
WO2021137196A1 (en) | 2021-07-08 |
EP4084696A1 (en) | 2022-11-09 |
CA3166517A1 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023510205A (ja) | 磁気共鳴イメージングにおけるデオキシヘモグロビン | |
Liu et al. | Cerebrovascular reactivity (CVR) MRI with CO2 challenge: a technical review | |
Jörgensen et al. | Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study | |
Wacker et al. | Changes in myocardial oxygenation and perfusion under pharmacological stress with dipyridamole: assessment using T* 2 and T1 measurements | |
Henderson et al. | The gravitational distribution of ventilation-perfusion ratio is more uniform in prone than supine posture in the normal human lung | |
Roeleveld et al. | Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension | |
Roest et al. | Biventricular response to supine physical exercise in young adults assessed with ultrafast magnetic resonance imaging | |
Miller et al. | Advances in functional and structural imaging of the human lung using proton MRI | |
US9750427B2 (en) | Magnetic resonance imaging of ventilation and perfusion in the lung | |
Wieslander et al. | Supine, prone, right and left gravitational effects on human pulmonary circulation | |
US9615754B2 (en) | Inducing and measuring myocardial oxygenation changes as a marker for heart disease | |
Ley et al. | Impact of oxygen inhalation on the pulmonary circulation: assessment by magnetic resonance (MR)-perfusion and MR-flow measurements | |
Poublanc et al. | Perfusion MRI using endogenous deoxyhemoglobin as a contrast agent: Preliminary data | |
Liu et al. | Use of real-time phase-contrast MRI to quantify the effect of spontaneous breathing on the cerebral arteries | |
Ramasawmy et al. | Blood volume measurement using cardiovascular magnetic resonance and ferumoxytol: preclinical validation | |
Sayin et al. | Assessing perfusion in steno-occlusive cerebrovascular disease using transient hypoxia-induced deoxyhemoglobin as a dynamic susceptibility contrast agent | |
Poon et al. | Assessment of pulmonary artery pulse wave velocity in children: an MRI pilot study | |
WO2023286040A1 (en) | Implementing a periodic deoxyhemoglobin signal | |
US20240285196A1 (en) | A method and system for determining a perfusion metric using deoxyhemoglobin as a contrast agent | |
US20230270348A1 (en) | System and method for determining arterial input function based on susceptibility contrast in the choroid plexus | |
WO2022269497A1 (en) | A method and system for determining a perfusion metric using deoxyhemoglobin as a contrast agent | |
EP4370184A1 (en) | Inducing deoxyhemoglobin as a contrast agent in a subject for mri | |
Duffin et al. | Cerebral perfusion metrics calculated directly, model-free, from a hypoxia-induced step change in deoxyhemoglobin | |
WO2023161901A1 (en) | Dynamic susceptibility contrast using a pre-determined arterial input function | |
Goldfarb et al. | Effects of supplemental oxygen on cardiovascular magnetic resonance water proton relaxation time constant measurements (T1, T2 and T2*) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220711 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230420 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230706 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230810 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231220 |